Origin and survival pathways of cancer stem cells in thyroid cancers

doi:10.16352/j.issn.1001-6325.2022.02.017

Abstract

Abstract: More and more attentions were being paid to the study of tumor stem cells. It has been demonstrated that tumor stem cells were present in both differentiated thyroid cancer with a good prognosis as papillary or follicular cancer and undifferentiated ones with poor prognosis. Thyroid cancer stem cells (TCSCs) play a major role in tumor genesis, progression and metastasis, and may even be the root of recurrence and drug resistance in thyroid cancers. Therefore, the study of TCSCs is great importance to thyroid cancer treatment. In this paper, the authors reviewed the latest researches progress on the origin and survival pathways of TCSCs.

Key words: thyroid cancers, cancer stem cells, origin, survival pathway

CLC Number:

R736.1

XIE Li-jun, ZHU Gao-hong, ZHAO Ji-hua, ZHANG Hai-bo, WANG Jiao. Origin and survival pathways of cancer stem cells in thyroid cancers[J]. Basic & Clinical Medicine, 2022, 42(2): 321-324.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2022.02.017

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2022/V42/I2/321

References

[1]Coelho M, Raposo L, Goodfellow BJ, et al. The potential of metabolomics in the diagnosis of thyroid cancer[J]. Int J Mol Sci, 2020,21:5272.doi:10.3390/ijms21155272.
[2]Asa SL. The current histologic classification of thyroid cancer[J]. Endocrinol Metab Clin North Am, 2019,48: 1-22.
[3]高伟波, 陈书长, 赵春华. 肿瘤干细胞与肿瘤耐药[J]. 基础医学与临床, 2006, 26:662-667.
[4]Han SA, Jang JH, Won KY, et al. Prognostic value of putative cancer stem cell markers (CD24, CD44, CD133, and ALDH1) in human papillary thyroid car-cinoma[J]. Pathol Res Pract, 2017,213:956-963.
[5]Hardin H, Helein H, Meyer K, et al. Thyroid cancer stem-like cell exosomes: regulation of EMT via transfer of incRNAs[J]. Lab Invest, 2018, 98: 1133-1142.
[6]Cho JM, Lee HJ, Chung JH, et al. Papillary thyroid cancer tumor spheres cultured by passaging without sorting exhibit cancer stemness[J]. Anticancer Res, 2020, 40:3801-3809.
[7]Haghpanah V, Fallah P, Naderi M, et al. Cancer stem-like cell behavior in anaplastic thyroid cancer: a challenging dilemma[J]. Life Sci, 2016, 146:34-39.
[8]Todaro M, Iovino F, Eterno V, et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells.[J]. Cancer Res, 2010, 70:8874-8885.
[9]Yuji N, Mika S, Norisato M. Cancer stem cells in the thyroid[J]. Front Endocrinol(Lausanne), 2016, 7:20.doi:10.3389/fendo.2016.00020.
[10]Shimamura M, Nagayama Y, Matsuse M, et al. Analysis of multiple markers for cancer stem-like cells in human thyroid carcinoma cell lines[J]. Endocr J, 2014, 61:481-490.
[11]Shiraiwa K, Matsuse M, Nakazawa Y,et al. JAK/STAT3 and NF-κB signaling pathways regulate cancer stem-cell properties in anaplastic thyroid cancer cells.[J]. Thyroid, 2019,29:674-682.
[12]Rao AS, Kremenevskaja N, von Wasielewski R, et al. Wnt/beta-catenin signaling mediates antineoplastic effects of imatinib mesylate (gleevec) in anaplastic thyroid cancer[J]. J Clin Endocrinol Metab, 2006, 91:159-168.
[13]许力凡, 张记, 田志强,等. 肿瘤抗药性的表观遗传学调控机制[J]. 基础医学与临床, 2013, 33:1638-1641.
[14]Zhu G, Xie L, Miller D. Expression of microRNAs in thyroid carcinoma[J].Methods Mol Biol, 2017, 1717: 261-280.
[15]Ravi N, Yang M, Mylona N, et al. Global RNA expression and DNA methylation patterns in primary anaplastic thyroid cancer[J]. Cancers, 2020, 12:680.doi:10.3390/cancers12030680.
[16]Kotian S, Zhang L, Boufraqech M,et al. Dual Inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases[J]. Clin Cancer Res,2017,23:5044-5054.
[17]Lin CL, Tsai ML, Lin CY, et al. HDAC1 and HDAC2 double knockout triggers cell apoptosis in advanced thyroid cancer[J]. Int J Mol Sci, 2019, 20. doi: 10.3390/ijms20020454.
[18]Xie Z, X Li, He Y, et al. Immune cell confrontation in the papillary thyroid carcinoma microenvironment[J]. Front Endocrinol(Lausanne), 2020,11:570604. doi: 10.3389/fendo.2020.570604.
[19]Varricchi G, Loffredo S, Marone G, et al. The immune landscape of thyroid cancer in the context of immune checkpoint inhibition[J]. Int J Mol Sci, 2019, 20:3934. doi:10.3390/ijms20163934.
[20]Kim MJ, Sun HJ, Song YS, et al. CXCL16 positively correlated with M2-macrophage infiltration, enhanced angiogenesis, and poor prognosis in thyroid cancer[J]. Sci Rep,2019, 16;9:13288. doi: 10.1038/s41598-019-49613-z.
[21]Croce L, Coperchini F, Magri F, et al. The multifaceted anti-cancer effects of BRAF-inhibitors[J]. Oncotarget, 2019, 10:6623-6640.
[22]Mario R, Francesca C, Francesco L, et al. Role of chemokines in thyroid cancer microenvironment:is CXCL8 the main player?[J]. Front Endocrinol(Lausanne), 2018, 9:314. doi: 10.3389/fendo.2018.00314.
[23]Bauerle KT, Schweppe RE, Lund G, et al. Nuclear factor κB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8.[J]. J Clin Endocrinol Metab, 2014,99:E1436-1444.
[24]Zheng R, Chen G, Li X, et al. Effect of IL-6 on proliferation of human thyroid anaplastic cancer stem cells[J]. Int J Clin Exp Pathol, 2019, 12:3992-4001.